A longer version of this story appears at Marijuana Business Daily International.
Sales of medical marijuana in Denmark posted healthy gains in the third quarter of 2020, coinciding with the launch of GW Pharmaceuticals’ CBD drug Epidiolex.
Overall sales of all medial cannabis products grew from about 13 million Danish Krones ($2 million) in the second quarter to almost 16 million Danish Krones in the third quarter, representing a gain of more than 20%.
But revenue within the country’s pilot program, which allows sales of flower and oil without marketing authorization, remains small and far from the peak seen one year ago.
In the third quarter of 2020, only 12.5% of total revenue generated by medical cannabis sales came from products sold as part of the pilot program, official data shows.
That is down from early 2019, when transactions in the pilot program represented 40% of the total medical cannabis sales.
The biggest change from the previous quarter was a meaningful increase of sales in the category of finished pharmaceutical products with marketing authorization, explained by the start of GW Pharmaceuticals’ Epidiolex sales.
The category of magistral preparations – medicines prepared in a pharmacy from isolated THC and/or CBD – decreased coinciding with the start of